McKesson MCK Business Segments
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Business | ||||||
| Medical-Surgical Solutions | $2.87B-4.1% | $2.99B+1.5% | $2.95B+9.1% | $2.7B-5.3% | $2.85B-3.3% | |
| North American Pharmaceutical | $79.12B-10.4% | $88.32B+2.1% | $86.48B+4.5% | $82.73B+7.5% | $76.94B-5.2% | |
| Oncology & Multispecialty | $12.71B-2.3% | $13.01B+8.0% | $12.04B+13.0% | $10.66B+13.0% | $9.43B-0.7% | |
| Prescription Technology Solutions | $1.5B-0.3% | $1.5B+9.0% | $1.38B-4.0% | $1.43B+7.1% | $1.34B-2.3% | |
| Subtotal by Business | ||||||
| Medical-Surgical Solutions | $232M-12.5% | $265M+20.5% | $220M-0.5% | $221M-2.6% | $227M-15.6% | |
| North American Pharmaceutical | $1.16B+9.7% | $1.06B+23.8% | $852M+43.4% | $594M-48.4% | $1.15B+54.8% | |
| Oncology & Multispecialty | $301M-1.0% | $304M-8.4% | $332M+56.6% | $212M-2.3% | $217M+7.4% | |
| Prescription Technology Solutions | $286M+9.6% | $261M+7.0% | $244M-3.6% | $253M+2.0% | $248M+13.2% | |
| Total other segment expense, net by Business | ||||||
| Medical-Surgical Solutions | $2.64B-3.3% | $2.73B0.0% | $2.73B+10.0% | $2.48B-5.6% | $2.63B-2.0% | |
| North American Pharmaceutical | $77.96B-10.7% | $87.27B+1.9% | $85.63B+4.3% | $82.14B+8.4% | $75.79B-5.8% | |
| Oncology & Multispecialty | $12.41B-2.3% | $12.71B+8.5% | $11.71B+12.1% | $10.45B+13.4% | $9.21B-0.8% | |
| Prescription Technology Solutions | $1.21B-2.4% | $1.24B+9.5% | $1.13B-4.1% | $1.18B+8.2% | $1.09B-5.3% | |
| Revenue derived from services (less than) (as a percent) by Business | ||||||
| Prescription Technology Solutions | 7%-29.0pp | 36%-1.0pp | 37%-1.0pp | 38%+31.0pp | 7%-29.0pp | |
| Total segment expenditures for long-lived assets by Business | ||||||
| Medical-Surgical Solutions | $13M-45.8% | $24M-25.0% | $32M+28.0% | $25M-26.5% | $34M-5.6% | |
| North American Pharmaceutical | $115M+36.9% | $84M+13.5% | $74M+21.3% | $61M-28.2% | $85M+37.1% | |
| Oncology & Multispecialty | $14M-17.6% | $17M-26.1% | $23M-4.2% | $24M0.0% | $24M-11.1% | |
| Prescription Technology Solutions | $2M+100% | $1M— | $0-100% | $1M0.0% | $1M-66.7% | |
| Other by Business | ||||||
| Medical-Surgical Solutions | $500K0.0% | $500K0.0% | $500K0.0% | $500K— | $0+100% | |
| North American Pharmaceutical | -$1M— | —— | —— | —— | -$1.25M0.0% | |
| Oncology & Multispecialty | $0— | $0— | $0— | $0+100% | -$250K0.0% | |
| Prescription Technology Solutions | $0— | —— | —— | —— | -$1M— | |
| Total segment depreciation and amortization by Business | ||||||
| Medical-Surgical Solutions | $25M-3.8% | $26M+13.0% | $23M+4.5% | $22M-8.3% | $24M+4.3% | |
| North American Pharmaceutical | $36M+5.9% | $34M+6.3% | $32M0.0% | $32M+3.2% | $31M-6.1% | |
| Oncology & Multispecialty | $64M+1.6% | $63M-11.3% | $71M+69.0% | $42M+16.7% | $36M-2.7% | |
| Prescription Technology Solutions | $20M-4.8% | $21M+5.0% | $20M-4.8% | $21M0.0% | $21M-4.5% | |
| Foreign currency translation adjustments, net by Business | ||||||
| Medical-Surgical Solutions | $0— | $0— | $0— | $0— | $0— | |
| Oncology & Multispecialty | $0— | $0— | —— | —— | $0— | |
| Prescription Technology Solutions | $0— | $0— | $0— | $0— | $0— | |
| Total reserve balance by Business | ||||||
| Medical-Surgical Solutions | $10M+66.7% | $6M-84.6% | $39M-31.6% | $57M-36.7% | $90M-18.9% | |
| North American Pharmaceutical | $18M+28.6% | $14M0.0% | $14M— | —— | $11M— | |
| Prescription Technology Solutions | $3M— | $0— | $0-100% | $1M0.0% | $1M-50.0% | |
| Other adjustments by Business | ||||||
| Medical-Surgical Solutions | $0— | $0— | $0— | $0-100% | $83M— | |
| North American Pharmaceutical | $0— | $0— | —— | —— | $1.25M0.0% | |
| Prescription Technology Solutions | -$1M— | $0— | $0— | $0+100% | -$8M— | |
| Non-cash charges by Business | ||||||
| Medical-Surgical Solutions | -$19M-273% | $11M— | $0— | $0-100% | $8M+33.3% | |
| North American Pharmaceutical | $14M+567% | -$3M— | —— | —— | $14.5M0.0% | |
| Prescription Technology Solutions | $17M— | $0— | $0— | $0-100% | $7M— | |
| Severance and employee-related costs, net by Business | ||||||
| North American Pharmaceutical | $5M— | $0-100% | $4M— | $0+100% | -$4M— | |
| Restructuring Charges by Business | ||||||
| Medical-Surgical Solutions | $10M+433% | -$3M-116% | $19M+11.8% | $17M-51.4% | $35M+84.2% | |
| North American Pharmaceutical | $16M+1,500% | $1M-83.3% | $6M+500% | $1M— | —— | |
| Prescription Technology Solutions | $20M— | $0— | $0— | $0-100% | $7M— | |
| Payments for Restructuring by Business | ||||||
| Medical-Surgical Solutions | $3M-93.0% | $43M+16.2% | $37M-26.0% | $50M+4.2% | $48M+9.1% | |
| North American Pharmaceutical | $1M— | —— | —— | —— | $2M0.0% | |
| Oncology & Multispecialty | $0— | $0— | $0— | $0-100% | $500K0.0% | |
| Exit and other-related costs by Business | ||||||
| Medical-Surgical Solutions | $9M+350% | $2M-85.7% | $14M+16.7% | $12M-57.1% | $28M+47.4% | |
| North American Pharmaceutical | $1M— | $0-100% | $1M0.0% | $1M-66.7% | $3M+200% | |
| Goodwill, transfer to held-for-sale by Business | ||||||
| Medical-Surgical Solutions | $0— | $0— | $0— | $0— | $0— | |
| North American Pharmaceutical | $0— | $0— | —— | —— | $11.5M0.0% | |
| Oncology & Multispecialty | $2.25M0.0% | $2.25M0.0% | $2.25M0.0% | $2.25M— | $0— | |
| Prescription Technology Solutions | $0— | $0— | $0— | $0— | $0— | |
| Asset impairments and accelerated depreciation by Business | ||||||
| North American Pharmaceutical | $10M+900% | $1M0.0% | $1M— | $0— | —— | |
| Goodwill by Business | ||||||
| Medical-Surgical Solutions | $2.51B0.0% | $2.51B0.0% | $2.51B0.0% | $2.51B0.0% | $2.51B0.0% | |
| North American Pharmaceutical | $2.78B-0.7% | $2.8B+0.7% | $2.78B— | —— | $2.74B— | |
| Oncology & Multispecialty | $3.96B+0.3% | $3.95B+0.6% | $3.93B— | —— | $2.72B— | |
| Prescription Technology Solutions | $2.07B0.0% | $2.07B0.0% | $2.07B0.0% | $2.07B+1.9% | $2.03B+0.1% | |
| Goodwill acquired by Business | ||||||
| Medical-Surgical Solutions | $0— | $0— | $0— | $0— | $0— | |
| North American Pharmaceutical | $0— | $0— | —— | —— | $250K0.0% | |
| Total long-lived assets by Geography | ||||||
| Foreign | $255M+0.4% | $254M-2.7% | $261M-20.9% | $330M+7.8% | $306M— | |
| United States | $3.18B+1.6% | $3.13B+1.0% | $3.1B+4.9% | $2.95B+2.6% | $2.88B— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does McKesson break its business down?
- McKesson (MCK) reports total revenues by business across 4 parts — Medical-Surgical Solutions, North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions. Each is extracted from the segment footnotes and tracked over time.
- Where does McKesson's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in McKesson's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
